RhAPPcast
By Rheumatology Advanced Practice Providers (RhAPP)
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 203
Description
This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).
Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases.
| Episode | Date |
|---|---|
|
RhAPPcast: Switch, Don’t Cycle: Interpreting the SELECT-SWITCH Trial and What It Means for RA Care
|
Jul 13, 2026 |
|
RhAPPcast: Applying SLE Treatment Principles in Everyday Practice
|
Jul 09, 2026 |
|
RhAPPcast: Pharmacists in Rheumatology
|
Jul 07, 2026 |
|
RhAPPcast: EULAR Osteoporosis RhAPP Up: Part 2
|
Jul 03, 2026 |
|
RhAPPcast: EULAR Osteoporosis RhAPP Up: Part 3
|
Jul 03, 2026 |
|
RhAPPcast: EULAR Osteoporosis RhAPP Up: Part 1
|
Jul 01, 2026 |
|
RhAPPcast: EULAR PsA RhAPP Up: Part 3
|
Jun 29, 2026 |
|
RhAPPcast: EULAR PsA RhAPP Up: Part 2
|
Jun 26, 2026 |
|
RhAPPcast: EULAR PsA RhAPP UP: Part 1
|
Jun 24, 2026 |
|
RhAPPcast: EULAR ILD RhAPP Up: Part 3
|
Jun 22, 2026 |
|
RhAPPcast: EULAR ILD RhAPP Up: Part 2
|
Jun 18, 2026 |
|
RhAPPcast: EULAR ILD RhAPP UP: Part 1
|
Jun 16, 2026 |
|
RhAPPcast: TYK2 Inhibition in PsA, Sjögren’s and SLE: What APPs Need to Know as Future Uses Emerge
|
Jun 11, 2026 |
|
Journal Club Review: SURMOUNT-5
|
Jun 09, 2026 |
|
Medication Review: Deucravacitinib Dosing, Administration, DDIs, & Safety in Clinical Practice
|
Jun 04, 2026 |
|
Podcast: Weight, Wellness, and PsA: Empowering Conversations & Action in the Rheumatology Clinic
|
Jun 02, 2026 |
|
FAQ: TYK2/STAT Signaling: The Immunologic Rationale for TYK2 Therapy in SLE & Sjögren’s Disease
|
May 28, 2026 |
|
RhAPPcast: From Prescription to Possession: Understanding Medicare Access & Cap and Smooth
|
May 26, 2026 |
|
FAQ: What Is Minimal Disease Activity in PsA and How Does Deucravacitinib Perform at 52 Weeks?
|
May 21, 2026 |
|
FAQ: What Guideline Recommendations Exist Pertaining to Managing obesity in Patients With PsA?
|
May 19, 2026 |
|
RhAPPcast: Identification and Diagnosis of XLH: A Story of Family History
|
May 14, 2026 |
|
Medication Review: What Is the Safety Profile of Tirzepatide?
|
May 12, 2026 |
|
Medication Review: Tirzepatide Starting Dose & Titration for Optimal Outcomes
|
May 07, 2026 |
|
Journal Club Review: SOLSTICE Publication
|
May 05, 2026 |
|
FAQ: How Can HPP Be Misdiagnosed in Rheumatology and What Are Common Diagnostic Pitfalls?
|
Apr 30, 2026 |
|
Medication Review: Describe The Mechanism of Action of Tirzepatide
|
Apr 28, 2026 |
|
Journal Club Review: APEX Publication
|
Apr 25, 2026 |
|
RhAPPcast: Diagnostic Crossroads: Clues, Pitfalls, and the Journey to an HPP Diagnosis
|
Apr 23, 2026 |
|
Journal Club Review: The Challenge of Hypophosphatasia Diagnosis in Adults
|
Apr 21, 2026 |
|
FAQ: How Does Weight Reduction Impact PsA Outcomes?
|
Apr 16, 2026 |
|
FAQ: What Are the Neuromuscular and Functional Burdens of Living With HPP?
|
Apr 14, 2026 |
|
RhAPPcast: IVIG Unpacked
|
Apr 11, 2026 |
|
Journal Club Review: DISCOVER-2 Severe PsA Publication
|
Apr 09, 2026 |
|
FAQ: How Does Obesity Affect PsA Outcomes?
|
Apr 07, 2026 |
|
FAQ: What Skeletal and Dental Manifestations Might Indicate HPP?
|
Apr 02, 2026 |
|
RhAPPcast: SubQ Solutions: Induction and Maintenance in Moderately to Severely Active CD and UC
|
Mar 31, 2026 |
|
RhAPPcast: Upadacitinib in GCA: Interpreting the 2-Year SELECT-GCA Results
|
Mar 26, 2026 |
|
FAQ: What is the Importance of MRI in Assessing Axial Disease Manifestations in PsA?
|
Mar 24, 2026 |
|
FAQ: How Does Obesity Impact the Immune System?
|
Mar 19, 2026 |
|
FAQ: What Role Does Power Doppler Ultrasound Play in Detecting Subclinical Inflammation/Enthesitis?
|
Mar 17, 2026 |
|
RhAPPcast: Unpacking the Genetics: Low ALP
|
Mar 12, 2026 |
|
FAQ: What Is the Efficacy of Switching MOA to Guselkumab After Inadequate Response to a single TNFi?
|
Mar 10, 2026 |
|
Podcast: Inflammation Intersection: A Rheum-Gi Dialogue
|
Mar 05, 2026 |
|
RhAPPcast: Protecting Joints: Inhibiting Structural Damage in PsA With Guselkumab
|
Mar 03, 2026 |
|
FAQ: How Can Clinicians Best Approach Talking to Patients With PsA About Weight Management?
|
Feb 26, 2026 |
|
Med Review: What is the Safety and Efficacy Profile of Guselkumab in Juvenile Psoriatic Arthritis?
|
Feb 25, 2026 |
|
Medication Review: Anti-Drug Antibody Development With Guselkumab in Psoriasis, PsA & IBD
|
Feb 24, 2026 |
|
FAQ: What Role Does Tissue-Nonspecific Alkaline Phosphatase (TNSALP) Play in HPP?
|
Feb 19, 2026 |
|
Medication Review: Laboratory Monitoring for Guselkumab in Psoriasis, PsA, and IBD
|
Feb 17, 2026 |
|
Podcast: Inflammation Amplified: Understanding the PsA—Obesity Connection
|
Feb 12, 2026 |
|
Medication Review: Safety and Efficacy of Guselkumab in Crohn’s Disease and Ulcerative Colitis
|
Feb 10, 2026 |
|
Across The Rheum Podcast: Part 3 - Clinical Utility and Positioning of IL-23 Agents
|
Feb 06, 2026 |
|
Podcast: Under the Surface: Exploring the HPP Diagnosis in Adulthood
|
Feb 05, 2026 |
|
FAQ: Screening Tools APPs Use to Identify PsA, SpA, or IBD and Refer Early
|
Feb 03, 2026 |
|
FAQ: What Validated Screening Tools Identify PsA/SpA or IBD for Rheumatology or GI Referral?
|
Feb 03, 2026 |
|
Across The Rheum Podcast: Part 2 - Currently Available IL-23 Agents
|
Jan 30, 2026 |
|
Journal Club: HPP Diagnosis—Current State of the Art & Proposed Criteria for Children and Adults
|
Jan 29, 2026 |
|
Med Review: What is the Safety and Efficacy Profile of Guselkumab in Juvenile Psoriatic Arthritis?
|
Jan 27, 2026 |
|
Across The Rheum Podcast: Part 1: Immunology of IL-23
|
Jan 23, 2026 |
|
RhAPPcast: Born with Burden: Understanding the Pediatric Presentation of HPP
|
Jan 22, 2026 |
|
RhAPPcast: Unpacking the Differences: IL-23 Inhibitors in Focus
|
Jan 20, 2026 |
|
FAQ: What is Hypophosphatasia and How Does It Present Across the Lifespan?
|
Jan 15, 2026 |
|
Journal Club: Guselkumab Binds To CD64+ IL-23–Producing Myeloid Cells to Neutralize IL-23 Signals
|
Jan 13, 2026 |
|
FAQ: How Is Hypophosphatasia Diagnosed and What Are the Key Laboratory Markers?
|
Jan 08, 2026 |
|
What Is the Correlation of CD64 and IL-23 Expression in Inflamed Joint, Skin, and Gut Tissue?
|
Jan 06, 2026 |
|
FAQ: What is the Normal Role of CD64 in Innate and Adaptive Immunity?
|
Dec 23, 2025 |
|
Podcast: A Tale of Two Pediatric APPs
|
Dec 19, 2025 |
|
Medication Review: Describe the Dual Mechanism of Action of Guselkumab
|
Dec 16, 2025 |
|
FAQ: Why is the mvdH-S Score Used Most Often in PsA Trials?
|
Dec 11, 2025 |
|
FAQ: How Does The Design of APEX Differ From DISCOVER-2 To Enrich For Structural Damage?
|
Dec 09, 2025 |
|
The Conversation That Matters: Talking to Patients About Obesity and IMIDs
|
Dec 01, 2025 |
|
From Insight to Action: Practical Strategies to Improve Outcomes in Patients with Obesity and IMIDs
|
Nov 24, 2025 |
|
The Hidden Costs: Obesity’s Role in Suboptimal Outcomes and Healthcare Burden in IMIDs
|
Nov 17, 2025 |
|
Obesity and IMIDs: Unpacking the Epidemic and Its Far-Reaching Impacts
|
Nov 10, 2025 |
|
Live from RhAPP National: ILD & PH-ILD at the Rheum–Pulm Crossroads
|
Nov 06, 2025 |
|
RhAPPcast: ANCA-Associated Vasculitis: Insights From the RhAPP National Conference
|
Nov 03, 2025 |
|
FAQ: What is the clinical significance of structural damage in PsA?
|
Oct 30, 2025 |
|
Medication Review: Evidence for Guselkumab in Preventing Structural Damage Progression
|
Oct 28, 2025 |
|
RhAPPcast: Beyond Dryness: Key Takeaways from the Sjögren’s Symposium at RhAPP 2025
|
Oct 21, 2025 |
|
FAQ: What is the Effect of Guselkumab on Structural Damage in PsA?
|
Oct 16, 2025 |
|
FAQ: What is the Inflation Reduction Act & How Does It Impact Affordability of Biologic Therapies?
|
Oct 14, 2025 |
|
RhAPPcast: Unmasking XLH: Misdiagnosed and Misunderstood
|
Oct 09, 2025 |
|
RhAPPcast: Refractory PMR: When Steroids Aren’t Enough – Unmet Needs in Treatment
|
Oct 07, 2025 |
|
RhAPPcast: The Safety Conversation: Upadacitinib in the Treatment of GCA
|
Oct 02, 2025 |
|
Medication Review: What is the safety profile of sarilumab in PMR & RA?
|
Sep 30, 2025 |
|
RhAPPcast: Expanding the Arsenal: JAK Inhibitors in the Evolving GCA Landscape
|
Sep 18, 2025 |
|
Medication Review: How is Sarilumab Dosed & Administered for the Treatment of PMR & RA?
|
Sep 16, 2025 |
|
Medication Review: Key Patient Education When Starting Sarilumab for PMR or RA
|
Sep 09, 2025 |
|
RhAPPcast: Inside the Evidence: A Deep Dive into the SELECT-GCA Study
|
Sep 04, 2025 |
|
RhAPPcast: Laying the Foundation: Historical Approaches to GCA Treatment
|
Sep 02, 2025 |
|
FAQ: What is the Role of Sarilumab in Managing PMR?
|
Sep 02, 2025 |
|
Journal Club: Comparative Effectiveness of Sarilumab vs. Methotrexate as a Corticosteroid-Sparing Agent in Patients with Polymyalgia Rheumatica
|
Aug 26, 2025 |
|
FAQ: Choosing Between Steroid-Sparing Agents in PMR Treatment
|
Aug 19, 2025 |
|
Medication Review: Leflunomide Medication Review
|
Aug 14, 2025 |
|
RhAPPcast: Spotting the Signs: Recognizing and Diagnosing Giant Cell Arteritis
|
Aug 12, 2025 |
|
RhAPPcast: Foundations of PMR: Diagnosis, First-Line Therapy, and Tapering Strategies
|
Aug 05, 2025 |
|
Journal Club Review: Sarilumab for Relapse of Polymyalgia Rheumatica During Glucocorticoid Taper
|
Jul 22, 2025 |
|
FAQ: Steroid-Sparing Agent Consideration in PMR Management & What Options Are Available?
|
Jul 15, 2025 |
|
FAQ: What Are the Most Recent Treatment Guidelines for PMR, and What Are the Key Clinical Takeaways?
|
Jul 08, 2025 |
|
Medication Review: What is the Mechanism of Action of Methotrexate?
|
Jul 01, 2025 |
|
Journal Club Review: A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis
|
Jun 26, 2025 |
|
RhAPPcast: Understanding the TYK2/STAT Signaling Pathway in PsA: Clinical Implications and Beyond
|
Jun 19, 2025 |
|
Medication Review: Hydroxychloroquine Medication Review
|
Jun 17, 2025 |
|
FAQ: How Does the Selectivity of TYK2 and JAK Enzyme Inhibition Influence Their Safety Profiles
|
Jun 12, 2025 |
|
FAQ: According to the New 2024 ACR Guidelines for Lupus Nephritis, How Do You Monitor LN?
|
Jun 09, 2025 |
|
FAQ: Can You Recapture Response to IL-17i Therapy After Interruption or Discontinuation in Therapy?
|
Jun 04, 2025 |
|
FAQ: Steroid Tapering in Lupus Nephritis: Insights from the 2024 ACR Guidelines
|
May 29, 2025 |
|
Medication Review: What Is the Safety Profile of Deucravacitinib in PsO and PsA?
|
May 26, 2025 |
|
Journal Club Review: Voclosporin in Lupus Nephritis: New Insights on Efficacy & Safety from Clinical Trials
|
May 23, 2025 |
|
Medication Review: What is the Mechanism of Action of Deucravacitinib?
|
May 19, 2025 |
|
RhAPPcast: Practical Application: Integrating the New ACR LN Guidelines
|
May 16, 2025 |
|
Medication Review: What is the Real World Evidence of Guslekumab in PsA
|
May 14, 2025 |
|
FAQ: TYK2/STAT Pathway & Why TYK2 Therapy Works for Psoriasis and Psoriatic Arthritis
|
May 09, 2025 |
|
RhAPPcast: Decoding IL-17: Comparing and Contrasting IL-17A and IL-17F Inhibition
|
May 07, 2025 |
|
Medication Review: What Are the Clinically Meaningful Differences Between Voclosporin and Other Calcineurin Inhibitors?
|
May 02, 2025 |
|
RhAPPcast: ACR Psoriatic Arthritis RhAPPUP Part 1
|
Apr 30, 2025 |
|
RhAPPcast: ACR Psoriatic Arthritis RhAPPUp Part 2
|
Apr 30, 2025 |
|
RhAPPcast: ACR Psoriatic Arthritis RhAPPUp Part 3
|
Apr 30, 2025 |
|
RhAPPcast: The Relative Persistency and Effectiveness of Guselkumab in the Real-World
|
Apr 28, 2025 |
|
Medication Review: What is the safety profile of voclosporin and how should it be monitored?
|
Apr 24, 2025 |
|
Journal Club Review: Evaluating the Efficacy of Biologic With and Without Methotrexate
|
Apr 22, 2025 |
|
Journal Club Review: Voclosporin for Lupus Nephritis: Efficacy & Safety Insights from AURORA 1 & 2 Trials
|
Apr 18, 2025 |
|
Medication Review: Voclosporin Dosing, Administration, Adjustments & Interactions
|
Apr 17, 2025 |
|
Medication Review: What is the Efficacy of Guselkumab Across the GRAPPA Domains
|
Apr 16, 2025 |
|
FAQ: Are IL-17 Inhibitors Efficacious in Treating the Nail-DIP Complex in PsA?
|
Apr 09, 2025 |
|
FAQ: What Are CNIs? Treating Lupus Nephritis with the Latest ACR Guidelines
|
Apr 01, 2025 |
|
RhAPPcast: Elevating Care in LN: What the New ACR Guidelines Mean for Patients & How APPs can Apply Them
|
Mar 27, 2025 |
|
FAQ: How do IL-23 and IL-17 Inhibitors Differ in Clinical Efficacy
|
Mar 25, 2025 |
|
Journal Club Review: Ixekizumab vs. Guselkumab in Plaque Psoriasis (12-Week Trial Results)
|
Mar 19, 2025 |
|
Medication Review: What is Voclosporin and How Does it Work?
|
Mar 14, 2025 |
|
FAQ: According to the New 2024 ACR Guidelines for LN, What Are the Treatment Goals For Patients With LN?
|
Mar 13, 2025 |
|
Journal Club Review: Long-Term Safety of Guselkumab in Patients with Psoriatic Disease
|
Mar 12, 2025 |
|
RhAPPcast: Navigating Leflunomide Use in Pregnant Patients with Sjögren’s Syndrome
|
Mar 04, 2025 |
|
FAQ: According to the New 2024 ACR Guidelines, How Do You Treat LN?
|
Feb 28, 2025 |
|
FAQ: How Do You Interpret cDAPSA/DAPSA and MDA?
|
Feb 26, 2025 |
|
FAQ: How Do You Explain The Timing of Ixekizumab's Clinical Efficacy to Patients?
|
Feb 19, 2025 |
|
FAQ: 2024 ACR Guidelines: Screening & Diagnosing Lupus Nephritis in SLE Patients
|
Feb 14, 2025 |
|
RhAPPcast: LN Updates Unpacked: Insights on New ACR Guidelines
|
Feb 11, 2025 |
|
FAQ: How is Lupus Nephritis Defined?
|
Feb 07, 2025 |
|
FAQ: How Does Real-World Evidence Differ From Randomized Controlled Trials
|
Feb 05, 2025 |
|
FAQ: How Long Has It Been Since the Last ACR LN Guideline Updates, and Why Is This Significant?
|
Jan 31, 2025 |
|
Journal Club Review: Effectiveness of Methotrexate and Leflunomide as Corticoid-Sparing Drugs
|
Jan 28, 2025 |
|
RhAPPcast :The Clinical Utility of Guselkumab in Axial PsA
|
Jan 22, 2025 |
|
Journal Club Review: Efficacy & Safety of Ixekizumab ± Methotrexate in PsA (52-Week SPIRIT-H2H)
|
Jan 15, 2025 |
|
FAQ: How Do You Interpret Radiographic Progression Using Modified-vdHS or mTSS?
|
Jan 08, 2025 |
|
Medication Review: What Is the Efficacy of Ixekizumab Across the GRAPPA and EULAR Domains?
|
Dec 16, 2024 |
|
Medication Review: What Is the Safety Profile of Guselkumab in PsO and PsA?
|
Dec 11, 2024 |
|
FAQ: How Does Axial PsA Differ From AS Clinically, Genetically, and Radiographically?
|
Dec 04, 2024 |
|
Journal Club Review: 6-Month Guselkumab Effectiveness in PsA (Real-World CorEvitas Data)
|
Nov 20, 2024 |
|
RhAPPcast: Navigating the Complexities: IL-17 Inhibitors and IBD Risk
|
Nov 13, 2024 |
|
FAQ: Why is Binding CD64+ Important When Discussing IL23 Directed Therapy
|
Nov 06, 2024 |
|
Journal Club Review: Upadacitinib Safety & Efficacy in Pediatric JIA (Phase-1 Interim Data)
|
Nov 04, 2024 |
|
RhAPPcast: Lost Time: The Impact of Delaying Optimal Therapy in RA & SpA Patients Without Disease Control
|
Nov 01, 2024 |
|
Journal Club Review: 5-Year Data on Switching Upadacitinib & Adalimumab in RA
|
Oct 30, 2024 |
|
FAQ: Definition of Remission in Rheumatoid Arthritis & Likelihood with Advanced Therapies
|
Oct 25, 2024 |
|
Medication Review: How is Guselkumab dosed in PsO, PsA, and IBD
|
Oct 23, 2024 |
|
RhAPPcast: Navigating Remission in Rheumatoid Arthritis: Approaches, Advances, Impact, and Insights
|
Oct 18, 2024 |
|
FAQ: Variability in JAK Inhibition Specificity & Its Clinical Implications
|
Oct 16, 2024 |
|
RhAPPcast: CD64+ Binding Description, Relevance, and Potential Clinical Implications
|
Oct 16, 2024 |
|
FAQ: What Is the Difference Between Biosimilars and Generics?
|
Oct 14, 2024 |
|
FAQ: What Is the ORAL Surveillance Study and How Can It Be Applied to Clinical Practice?
|
Oct 11, 2024 |
|
FAQ: What is the Safety Profile of Ixekizumab in PsA and axSpa
|
Oct 09, 2024 |
|
Medication Review: What Is the Safety Profile of Upadacitinib Across Indications?
|
Oct 07, 2024 |
|
FAQ: Provide Immunologic Rationale For IL23 Directed Therapy in PsA, PsO, and IBD.
|
Oct 02, 2024 |
|
RhAPPcast: Biosimilars and The Patient Perspective
|
Sep 30, 2024 |
|
Medication Review: How Is Upadacitinib Dosed Across Rheumatologic Indications?
|
Sep 19, 2024 |
|
FAQ: Provide Immunologic Rationale for JAK-Directed Therapy in Rheumatic Disease
|
Sep 17, 2024 |
|
Medication Review: Describe the Mechanism of Action of Upadacitinib
|
Sep 13, 2024 |
|
FAQ: Provide Immunologic Rationale For IL17-Directed Therapy in PsA, AS, and nr-axSpA
|
Sep 11, 2024 |
|
FAQ: Describe the IL17-Induced Inflammatory Cascade
|
Sep 04, 2024 |
|
FAQ: Describe JAK-STAT Signaling in Inflammation
|
Sep 04, 2024 |
|
FAQ: What Does It Mean for a Biosimilar to Be Interchangeable and Why Is That Important?
|
Sep 02, 2024 |
|
Journal Club Review: Long-Term Efficacy and Safety of Guselkumab
|
Aug 28, 2024 |
|
Medication Review: What is Non-Responder Imputation and How is it Utilized in Clinical Trials
|
Aug 21, 2024 |
|
RhAPPcast: Biosimilars Unveiled - Empowering APPs for Better Patient Conversations
|
Aug 19, 2024 |
|
Medication Review: Describe The Mechanism of Action of Ixekizumab
|
Aug 14, 2024 |
|
FAQ: What is The Role of IL23/IL17 Axis in Rheumatic Disease
|
Aug 07, 2024 |
|
RhAPPcast: The IL23/IL17 Cascade and Implications in the Pathogenesis of PsA, PsO, and IBD
|
Jul 17, 2024 |
|
The 2024 RhAPP National Conference in Nashville, TN
|
Jul 10, 2024 |
|
FAQ: Describe The IL23/IL17 Axis
|
Jul 03, 2024 |
|
Journal Club Review: Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23
|
Jun 20, 2024 |
|
Medication Review: Describing the Mechanism of Action of Guselkumab
|
Jun 13, 2024 |
|
FAQ: Define, compare, and contrast humoral and cell-mediated immunity.
|
Jun 06, 2024 |
|
RhAPPcast Spotlight: Clinical Cornerstones with Lindsay Tom, PA-C
|
May 29, 2024 |
|
RhAPPcast Spotlight: Clinical Cornerstones with Cayla Alexander, DNP, ARNP
|
Apr 29, 2024 |
|
Breathing New Life: HRCT and PFTs in ILD with Corinne Young of APAPP
|
Apr 02, 2024 |
|
Spotlight: Clinical Cornerstones, Mary Elliott, PA-C
|
Feb 07, 2024 |
|
Leading the Way: Dr. John Cush on Rheumatology Leadership
|
Jan 17, 2024 |
|
Discussing Biosimilars With Patients
|
Dec 13, 2023 |
|
The Nocebo Effect
|
Dec 08, 2023 |
|
Voices for Change: Madelaine Feldman, MD of CSRO on Advocacy in Rheumatology
|
Nov 30, 2023 |
|
The Practical Use of Biosimilars in Gastroenterology APP Practice
|
Nov 08, 2023 |
|
The Practical Use of Biosimilars in Rheumatology APP Practice
|
Oct 30, 2023 |
|
The Benefits of Biosimilars
|
Oct 11, 2023 |
|
Managed Care and Biosimilars
|
Oct 03, 2023 |
|
Interchangeability & Switching of Biosimilars
|
Sep 15, 2023 |
|
Spotlight: Clinical Cornerstones, Daric Mueller, MS, PA-C
|
Aug 30, 2023 |
|
Biosimilar Extrapolation
|
Aug 23, 2023 |
|
The Difference Between Biosimilars & Generic Drugs
|
Aug 08, 2023 |
|
The Regulatory Pathway to Biosimilar Approval
|
Jul 25, 2023 |
|
Development of Biosimilars
|
Jul 13, 2023 |
|
From Idea to Impact: The RhAPP Origin Story
|
Jun 22, 2023 |
|
Biosimilars Series: What Are Biosimilars?
|
Jun 14, 2023 |